StockNews.com started coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a research report released on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.
RedHill Biopharma Trading Down 6.4 %
RedHill Biopharma stock opened at $5.86 on Wednesday. RedHill Biopharma has a 12 month low of $5.86 and a 12 month high of $31.50. The stock has a fifty day simple moving average of $7.19 and a two-hundred day simple moving average of $75.48. The firm has a market cap of $7.51 million, a price-to-earnings ratio of -0.59 and a beta of 3.69.
Hedge Funds Weigh In On RedHill Biopharma
A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC acquired a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned about 0.40% of RedHill Biopharma as of its most recent SEC filing. Institutional investors own 7.20% of the company’s stock.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
See Also
- Five stocks we like better than RedHill Biopharma
- The Role Economic Reports Play in a Successful Investment Strategy
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- 3 Warren Buffett Stocks to Buy Now
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
